Azitra, Inc.

Azitra, Inc. reported a net loss of $11.0 million for the fiscal year ended December 31, 2025, compared to a net loss of $9.0 million in the prior year, representing a 22% increase in losses. The company generated no revenue in FY 2025, consistent with its status as an early-stage clinical biopharmaceutical company that has not commenced commercial operations. Operating expenses totaled $11.0 million, primarily driven by general and administrative costs of $6.1 million and research and development expenses of $4.8 million. The company ended the period with $2.1 million in cash and cash equivalents, down from $4.6 million at the end of 2024, and reported an accumulated deficit of $68.5 million. Management's discussion indicates substantial doubt about the company's ability to continue as a going concern, with cash on hand expected to cover operations for only three months from the filing date.

Key Takeaways